+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 61 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.

Age: 18Years +All GendersPhase 3
106 locations
E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd, alone or combined with other treatments, in people with metastatic castration-resistant prostate cancer mCRPC. This study aims to understand how well participants tolerate the treatment, find a safe dose level for combination therapies, and monitor prostate-specific antigen PSA levels during treatment. The study is part of a larger master screening protocol and includes participants with advanced prostate cancer. Participants may receive one of several treatment plans docetaxel chemotherapy every three weeks for up to 10 cycles I-DXd alone every three weeks until side effects, disease progression, death, or withdrawal I-DXd combined with opevesostat after dose escalation until stopping criteria are met or I-DXd combined with an androgen receptor pathway inhibitor abiraterone or enzalutamide under similar conditions. Before each I-DXd dose, participants take medications to prevent nausea and vomiting. During the study, participants will have regular assessments including monitoring for treatment side effects, PSA response, and disease progression. Researchers will track dose-limiting toxicities, adverse events, and reasons for stopping treatment over periods ranging from about three weeks to over four years. Secondary measures include overall survival, radiographic progression-free survival, and time to pain progression. Participation may last several years, with ongoing safety and effectiveness evaluations carried out throughout this time.

Age: 18Years +All GendersPhase 1Phase 2
82 locations
E

Actively Recruiting

Researchers are investigating new treatments for people with high-risk non-muscle invasive bladder cancer HR NMIBC, a type of bladder cancer that affects the inner lining and has not spread to the muscle. This condition includes carcinoma in situ CIS, a flat cancer limited to the bladders surface. The study aims to find out if adding intismeran autogene to the standard Bacillus Calmette-Guerin BCG treatment can help patients live longer without their cancer growing, spreading, or returning. Participants receive either intismeran autogene combined with BCG or BCG alone. Intismeran autogene is given as a 1 mg intramuscular injection every 3 weeks for nine doses. BCG is administered as a 50 mg intravesicular instillation once weekly for 6 weeks initially, then during weeks 13-15, 25-27, 49-51, and 73-75. Some participants receive only intismeran autogene. The study follows these treatments in separate groups to compare outcomes. During the study, participants undergo assessments over up to approximately five years to measure event-free survival, recurrence-free survival, disease-specific survival, overall survival, and other health outcomes. Researchers track cancer response, monitor adverse events, and evaluate how long participants remain cancer-free. Regular visits and tests help monitor safety and treatment effects throughout the study period.

Age: 18Years +All GendersPhase 2
89 locations
E

Actively Recruiting

Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.

Age: 50Years - 85YearsAll GendersPhase 2
80 locations
P

Actively Recruiting

Researchers are evaluating new treatments for people with locally advanced or metastatic urothelial cancer UC that has worsened after previous therapies. This phase 3 trial aims to find out if sacituzumab tirumotecan sac-TMT, an investigational drug given by intravenous infusion, can help patients live longer compared to standard non-platinum chemotherapy options. The study is sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan at 4 mgkg every two weeks via IV infusion or one of three chemotherapy drugspaclitaxel, docetaxel, or vinfluninegiven every three weeks by IV infusion. Treatment continues until the disease progresses or side effects become unacceptable. Rescue medications may be given as needed according to approved guidelines during treatment. During the trial, participants will have regular assessments including imaging to measure disease status and evaluations of side effects and quality of life. The main outcome measured is overall survival up to about 40 months, along with secondary outcomes like progression-free survival, response rates, duration of response, and changes in quality of life scores. Safety and adverse events will be monitored throughout, with the study lasting until April 2030.

Age: 18Years +All GendersPhase 3
111 locations
S

Actively Recruiting

Researchers are investigating the potential neuroprotective effects of a dual orexin receptor antagonist DORA called Lemborexant in adults aged 40 to 65 years who have insomnia disorder. The study aims to find out whether Lemborexant reduces blood levels of biomarkers related to neurodegeneration, including phosphorylated TAU181, TAU217, amyloid beta 4042 ratio, Neurofilament Light Chain NFL, and Glial Fibrillary Acidic Protein GFAP, compared to a placebo. This is a randomized, placebo-controlled crossover study conducted to better understand these effects in people with insomnia. Participants will take 10 mg of Lemborexant orally each night for two weeks and also take a matching placebo nightly for two weeks, with a 2 to 4 week washout period between treatments. After each two-week treatment phase, participants will attend an overnight visit at the research laboratory lasting about 18 hours, during which various assessments like high-density EEG, functional near-infrared spectroscopy, questionnaires, and pupillometry will be conducted. Blood samples will be collected hourly for four hours after awakening during these overnight visits to measure biomarker levels. Participants will be involved in a screening visit followed by two treatment periods and corresponding overnight assessments. They will provide informed consent and be randomized to receive either Lemborexant or placebo first. The study team will monitor treatment effects through blood tests and various neurophysiological and behavioral assessments. The total participation involves three visits, including screening and two overnight study visits, with close monitoring of biomarker changes and safety throughout the study.

Age: 40Years - 65YearsAll GendersPhase 2
1 location
T

Actively Recruiting

Researchers are evaluating how changes in diet affect sleepiness, quality of life, and metabolic health in adults living with narcolepsy and idiopathic hypersomnia. This trial focuses on two dietary approaches a whole-food ketogenic diet and a standard whole-food diet, aiming to provide additional lifestyle options beyond medication for managing symptoms. This area of research is new for hypersomnolence conditions but builds on evidence of safety and benefits in other chronic and neurological conditions. The study is a 12-week randomized controlled trial with two groups. All participants start with a three-week period consuming a standard whole-food diet. After this run-in, they are randomly assigned to either continue the standard whole-food diet or switch to a whole-food ketogenic diet that limits carbohydrates to 30-50 grams per day to achieve nutritional ketosis. Both diets focus on unprocessed or minimally processed foods, with the ketogenic diet targeting specific ketone levels monitored through blood and urine tests. Participants will be involved in dietary changes and monitored for feasibility, tolerability, and compliance throughout the 12 weeks. Assessments include measures of sleep quality and sleepiness, metabolic health markers, mood, quality of life surveys, and dietary adherence using ketone levels and sleep diaries. Data collection involves interviews and questionnaires to understand patient experiences and preferences. The study aims to assess whether these diet changes can be sustained and improve health outcomes alongside usual care.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating a new inhaled form of melatonin compared to oral melatonin tablets in adults aged 55 and older who have insomnia. The trial aims to understand if inhaled melatonin affects sleep patterns, such as how quickly participants fall asleep, differently than oral tablets. This is an early phase 1, randomized open-label crossover study conducted to explore these potential differences in sleep quality and neuroinflammation markers. Participants will receive two treatments in different periods inhaled melatonin delivered by a pressurized inhaler at a dose of 100 micrograms two puffs nightly for two weeks, and oral melatonin tablets at a dose of 4 mg two tablets nightly for two weeks. After each treatment period, there is a one-week washout before crossing over to the other treatment. The study includes overnight stays in a sleep laboratory for sleep monitoring and blood collection visits to assess biomarkers. During the study, participants will visit the research center five times for screening, overnight sleep studies at the start of each treatment period, and blood collection after each treatment. They will complete daily sleep diaries to record their sleep quality during the two-week treatment periods. Researchers will measure sleep onset latency primarily and also assess sleep time, wakefulness after sleep onset, insomnia severity, and subjective sleep quality. Safety and adherence will be monitored throughout the study, which is expected to end in May 2026.

Age: 55Years +All GendersEarly Phase 1
1 location
O

Actively Recruiting

Researchers are evaluating D3S-003, an oral drug, in a first-in-human Phase 1 clinical trial for participants with advanced solid tumors that have a specific KRAS p.G12D mutation. This trial aims to assess the safety, tolerability, how the drug is processed by the body, its biological effects, and early signs of how well it might work. Participants must have cancers that have not responded to standard treatments or have no effective standard options, and tumors that can be measured by imaging. The study includes two parts of dose escalation to find the best dosing schedule once daily and twice daily dosing of D3S-003. Participants will receive the drug orally with doses gradually increased to evaluate safety and identify the maximum tolerated dose and recommended Phase 2 dose. The treatment period can last up to approximately seven months or until disease progression or unacceptable side effects occur. During the study, participants will have regular monitoring for side effects and safety from the screening visit until 30 days after the last dose. Researchers will measure drug levels in the blood and evaluate tumor response using standardized criteria. The primary outcomes include the number of participants experiencing dose-limiting toxicities and adverse events. The trial will last until January 2028, with frequent assessments during treatment cycles of 21 days each.

Age: 18Years +All GendersPhase 1
9 locations

1-10 of 61

1